Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Aytu Biopharma Inc
(NQ:
AYTU
)
2.440
-0.030 (-1.21%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Aytu Biopharma Inc
< Previous
1
2
3
4
5
6
7
8
Next >
12 Health Care Stocks Moving In Wednesday's After-Market Session
January 19, 2022
Gainers Acorda Therapeutics (NASDAQ:ACOR)...
Via
Benzinga
Aytu BioPharma Appoints Mark Oki as Chief Financial Officer
January 04, 2022
ENGLEWOOD, CO / ACCESSWIRE / January 4, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today...
From
Aytu BioPharma, Inc.
Via
AccessWire
Aytu BioPharma to Present at H.C. Wainwright BioConnect Conference
January 03, 2022
ENGLEWOOD, CO / ACCESSWIRE / January 3, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today...
From
Aytu BioPharma, Inc.
Via
AccessWire
12 Health Care Stocks Moving In Tuesday's After-Market Session
December 14, 2021
Gainers Star Equity Hldgs (NASDAQ:STRR) s...
Via
Benzinga
Investigation Announced for Investors in NASDAQ:AYTU Shares of Possible Violations of Securities Laws by Aytu BioScience, Inc
December 14, 2021
San Diego, CA -- (SBWIRE) -- 12/14/2021 -- Aytu BioScience, Inc is under investigation concerning potential securities laws violations in connection with certain financial statements.
Via
SBWire
Aytu BioPharma Announces FDA Clearance of Investigational New Drug (IND) Application for AR101/Enzastaurin in Vascular Ehlers-Danlos Syndrome
December 13, 2021
Pivotal clinical trial will begin in first half of 2022 ENGLEWOOD, CO / ACCESSWIRE / December 13, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel...
From
Aytu BioPharma, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
Legal
Product Safety
Regulatory
Aytu BioPharma Receives Orphan Drug Designation from FDA for AR101 for Treatment of Vascular Ehlers-Danlos Syndrome
December 08, 2021
ENGLEWOOD, CO / ACCESSWIRE / December 8, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products,...
From
Aytu BioPharma, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
Legal
Product Safety
Regulatory
Aytu BioScience, Inc. (NASDAQ: AYTU) Shareholder Notice: Investigation over Potential Wrongdoing
November 30, 2021
San Diego, CA -- (SBWIRE) -- 11/30/2021 -- Certain directors of Aytu BioScience, Inc are under investigation on over potential breaches of fiduciary dutie.
Via
SBWire
Aytu BioPharma Announces Issuance of First U.S. Patent Supporting Healight Ultraviolet-A Respiratory Catheter
November 23, 2021
ENGLEWOOD, CO / ACCESSWIRE / November 23, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products,...
From
Aytu BioPharma, Inc.
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
Aytu BioPharma Ranked Number 178 Fastest-Growing Company in North America on the 2021 Deloitte Technology Fast 50(TM)
November 17, 2021
ENGLEWOOD, CO / ACCESSWIRE / November 17, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products,...
From
Aytu BioPharma, Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Aytu BioPharma Reports First Quarter 2022 Financial Results
November 15, 2021
Quarterly net revenue increased 62% to $21.9 million Ended quarter with approximately $40.6 million in cash, cash equivalents and restricted cash Fully integrated and expanding RxConnect patient...
From
Aytu BioPharma, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Product Safety
The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More
November 14, 2021
Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at...
Via
Benzinga
Exposures
Product Safety
Aytu BioPharma, Inc. (NASDAQ:AYTU) Investor Alert: Investigation over Possible Violations of Securities Laws
November 09, 2021
San Diego, CA -- (SBWIRE) -- 11/09/2021 -- An investigation was announced for investors of Aytu BioPharma, Inc. (NASDAQ:AYTU) shares over potential securities laws violations by Aytu BioPharma, Inc....
Via
SBWire
Aytu BioPharma to Report First Quarter Fiscal 2022 Results and Provide Business Update on November 15, 2021
November 08, 2021
ENGLEWOOD, CO / ACCESSWIRE / November 8, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products,...
From
Aytu BioPharma, Inc.
Via
AccessWire
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
October 12, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11) AstraZeneca Plc (NASDAQ:...
Via
Benzinga
Exposures
COVID-19
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
October 08, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS)...
Via
Benzinga
Exposures
Product Safety
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
October 07, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) Enanta Pharmaceuticals, Inc...
Via
Benzinga
CORRECTION: Aytu BioPharma to Present at Upcoming September Investor Conferences
September 30, 2021
(This release corrects the previous one that was issued on September 7, 2021 to reflect the time of the Cantor Presentation being changed to 2:40 pm EST) ENGLEWOOD, CO / ACCESSWIRE / September 30, 2021...
From
Aytu BioPharma, Inc.
Via
AccessWire
The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
September 30, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc. (...
Via
Benzinga
Exposures
COVID-19
Recap: Aytu BioPharma Q4 Earnings
September 29, 2021
Aytu BioPharma(NASDAQ:AYTU) stock fell by 8.33% on Tuesday after the company reported its Q4 earnings results on Monday, September 27, 2021 at 04:01 PM. Here's what...
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
September 27, 2021
Gainers Paratek Pharmaceuticals (NASDAQ:PRTK...
Via
Benzinga
Aytu BioPharma Reports Fourth Quarter and Full-Year Fiscal 2021 Financial Results
September 27, 2021
Quarterly net revenue increased 74% sequentially to $23.5M; 138% year-over-year to $65.6M Ended quarter with approximately $50M in cash, cash equivalents and restricted cash Planned pivotal study for...
From
Aytu BioPharma, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Product Safety
Earnings Scheduled For September 27, 2021
September 27, 2021
Companies Reporting Before The Bell • S&W Seed (NASDAQ:SANW) is expected to report quarterly loss at $0.15 per share on revenue of $22.70 million. • iBio (...
Via
Benzinga
Aytu BioPharma to Report Fourth Quarter and Full Year Fiscal 2021 Results and Provide Business Update on September 27, 2021
September 23, 2021
ENGLEWOOD, CO / ACCESSWIRE / September 23, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products,...
From
Aytu BioPharma, Inc.
Via
AccessWire
The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs
September 22, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Acceleron Pharma Inc. (...
Via
Benzinga
The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data
September 21, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Cerevel Therapeutics...
Via
Benzinga
Exposures
COVID-19
The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold
September 17, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16) Bicycle Therapeutics plc (...
Via
Benzinga
Aytu BioPharma Announces Formation of New Scientific Advisory Board to Support Development of AR101 for Vascular Ehlers-Danlos Syndrome
September 09, 2021
Chaired by Dr. Hal Dietz and joined initially by Dr. Xavier Jeunemaitre, Dr. Shaine Morris, Dr. Bart Loeys, and Dr. Peter Byers with additional advisors to be added ENGLEWOOD, CO / ACCESSWIRE /...
From
Aytu BioPharma, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Regulatory
The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs
September 15, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 14) Alcon Inc. (NYSE: ALC)...
Via
Benzinga
Exposures
COVID-19
The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout
September 14, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 13) Abbott Laboratories (NYSE...
Via
Benzinga
Exposures
COVID-19
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.